Selected research
Market Structure
Global Neuropeptide Y Receptor Type 2 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Neuropeptide Y Receptor Type 2 market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Neuropeptide Y Receptor Type 2 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Neuropeptide Y Receptor Type 2 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Neuropeptide Y Receptor Type 2 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Neuropeptide Y Receptor Type 2 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Neuropeptide Y Receptor Type 2 include Novo Nordisk A/S, XL-protein GmbH and Gila Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Neuropeptide Y Receptor Type 2 market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Neuropeptide Y Receptor Type 2 and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Neuropeptide Y Receptor Type 2 sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neuropeptide Y Receptor Type 2 market size, projected growth trends, production technologies, key applications, and end-use industries.
Neuropeptide Y Receptor Type 2 Segment by Company
Novo Nordisk A/S
XL-protein GmbH
Gila Therapeutics Inc
Neuropeptide Y Receptor Type 2 Segment by Type
GT-002
NN-9748
XL-310
Others
Neuropeptide Y Receptor Type 2 Segment by Application
Obesity
Epilepsy
Type 2 Diabetes
Others
Neuropeptide Y Receptor Type 2 Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuropeptide Y Receptor Type 2 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuropeptide Y Receptor Type 2 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuropeptide Y Receptor Type 2.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Neuropeptide Y Receptor Type 2 market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuropeptide Y Receptor Type 2 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Neuropeptide Y Receptor Type 2 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Neuropeptide Y Receptor Type 2 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- GT-002
- NN-9748
- XL-310
- Others
Applications
- Obesity
- Epilepsy
- Type 2 Diabetes
- Others
Companies covered
- Novo Nordisk A/S
- XL-protein GmbH
- Gila Therapeutics Inc
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Neuropeptide Y Receptor Type 2 Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Neuropeptide Y Receptor Type 2 Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Neuropeptide Y Receptor Type 2 Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Neuropeptide Y Receptor Type 2 Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Neuropeptide Y Receptor Type 2 Market Dynamics
- 2.1 Neuropeptide Y Receptor Type 2 Industry Trends
- 2.2 Neuropeptide Y Receptor Type 2 Industry Drivers
- 2.3 Neuropeptide Y Receptor Type 2 Industry Opportunities and Challenges
- 2.4 Neuropeptide Y Receptor Type 2 Industry Restraints
3 Neuropeptide Y Receptor Type 2 Market by Manufacturers
- 3.1 Global Neuropeptide Y Receptor Type 2 Revenue by Manufacturers (2021-2026)
- 3.2 Global Neuropeptide Y Receptor Type 2 Sales by Manufacturers (2021-2026)
- 3.3 Global Neuropeptide Y Receptor Type 2 Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Neuropeptide Y Receptor Type 2 Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Neuropeptide Y Receptor Type 2 Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Neuropeptide Y Receptor Type 2 Manufacturers, Product Type & Application
- 3.7 Global Neuropeptide Y Receptor Type 2 Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Neuropeptide Y Receptor Type 2 Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Neuropeptide Y Receptor Type 2 Players Market Share by Revenue in 2025
- 3.8.3 2025 Neuropeptide Y Receptor Type 2 Tier 1, Tier 2, and Tier 3
4 Neuropeptide Y Receptor Type 2 Market by Type
- 4.1 Neuropeptide Y Receptor Type 2 Type Introduction
- 4.1.1 GT-002
- 4.1.2 NN-9748
- 4.1.3 XL-310
- 4.1.4 Others
- 4.2 Global Neuropeptide Y Receptor Type 2 Sales by Type
- 4.2.1 Global Neuropeptide Y Receptor Type 2 Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Neuropeptide Y Receptor Type 2 Sales by Type (2021-2032)
- 4.2.3 Global Neuropeptide Y Receptor Type 2 Sales Market Share by Type (2021-2032)
- 4.3 Global Neuropeptide Y Receptor Type 2 Revenue by Type
- 4.3.1 Global Neuropeptide Y Receptor Type 2 Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Neuropeptide Y Receptor Type 2 Revenue by Type (2021-2032)
- 4.3.3 Global Neuropeptide Y Receptor Type 2 Revenue Market Share by Type (2021-2032)
5 Neuropeptide Y Receptor Type 2 Market by Application
- 5.1 Neuropeptide Y Receptor Type 2 Application Introduction
- 5.1.1 Obesity
- 5.1.2 Epilepsy
- 5.1.3 Type 2 Diabetes
- 5.1.4 Others
- 5.2 Global Neuropeptide Y Receptor Type 2 Sales by Application
- 5.2.1 Global Neuropeptide Y Receptor Type 2 Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Neuropeptide Y Receptor Type 2 Sales by Application (2021-2032)
- 5.2.3 Global Neuropeptide Y Receptor Type 2 Sales Market Share by Application (2021-2032)
- 5.3 Global Neuropeptide Y Receptor Type 2 Revenue by Application
- 5.3.1 Global Neuropeptide Y Receptor Type 2 Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Neuropeptide Y Receptor Type 2 Revenue by Application (2021-2032)
- 5.3.3 Global Neuropeptide Y Receptor Type 2 Revenue Market Share by Application (2021-2032)
6 Global Neuropeptide Y Receptor Type 2 Sales by Region
- 6.1 Global Neuropeptide Y Receptor Type 2 Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Neuropeptide Y Receptor Type 2 Sales by Region (2021-2032)
- 6.2.1 Global Neuropeptide Y Receptor Type 2 Sales by Region (2021-2026)
- 6.2.2 Global Neuropeptide Y Receptor Type 2 Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Neuropeptide Y Receptor Type 2 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Neuropeptide Y Receptor Type 2 Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Neuropeptide Y Receptor Type 2 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Neuropeptide Y Receptor Type 2 Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Neuropeptide Y Receptor Type 2 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Neuropeptide Y Receptor Type 2 Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Neuropeptide Y Receptor Type 2 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Neuropeptide Y Receptor Type 2 Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Neuropeptide Y Receptor Type 2 Revenue by Region
- 7.1 Global Neuropeptide Y Receptor Type 2 Revenue by Region
- 7.1.1 Global Neuropeptide Y Receptor Type 2 Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Neuropeptide Y Receptor Type 2 Revenue by Region (2021-2026)
- 7.1.3 Global Neuropeptide Y Receptor Type 2 Revenue by Region (2027-2032)
- 7.1.4 Global Neuropeptide Y Receptor Type 2 Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Neuropeptide Y Receptor Type 2 Revenue (2021-2032)
- 7.2.2 North America Neuropeptide Y Receptor Type 2 Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Neuropeptide Y Receptor Type 2 Revenue (2021-2032)
- 7.3.2 Europe Neuropeptide Y Receptor Type 2 Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Neuropeptide Y Receptor Type 2 Revenue (2021-2032)
- 7.4.2 Asia-Pacific Neuropeptide Y Receptor Type 2 Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Neuropeptide Y Receptor Type 2 Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Neuropeptide Y Receptor Type 2 Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Novo Nordisk A/S
- 8.1.1 Novo Nordisk A/S Company Information
- 8.1.2 Novo Nordisk A/S Business Overview
- 8.1.3 Novo Nordisk A/S Neuropeptide Y Receptor Type 2 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Novo Nordisk A/S Neuropeptide Y Receptor Type 2 Product Portfolio
- 8.1.5 Novo Nordisk A/S Recent Developments
- 8.2 XL-protein GmbH
- 8.2.1 XL-protein GmbH Company Information
- 8.2.2 XL-protein GmbH Business Overview
- 8.2.3 XL-protein GmbH Neuropeptide Y Receptor Type 2 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 XL-protein GmbH Neuropeptide Y Receptor Type 2 Product Portfolio
- 8.2.5 XL-protein GmbH Recent Developments
- 8.3 Gila Therapeutics Inc
- 8.3.1 Gila Therapeutics Inc Company Information
- 8.3.2 Gila Therapeutics Inc Business Overview
- 8.3.3 Gila Therapeutics Inc Neuropeptide Y Receptor Type 2 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Gila Therapeutics Inc Neuropeptide Y Receptor Type 2 Product Portfolio
- 8.3.5 Gila Therapeutics Inc Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Neuropeptide Y Receptor Type 2 Value Chain Analysis
- 9.1.1 Neuropeptide Y Receptor Type 2 Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Neuropeptide Y Receptor Type 2 Production Mode & Process
- 9.2 Neuropeptide Y Receptor Type 2 Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Neuropeptide Y Receptor Type 2 Distributors
- 9.2.3 Neuropeptide Y Receptor Type 2 Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst